Bipoprojektsp. z o.o.

KRS: NIP: REGON:

Overview

Status
Active
Registry date
2005-08-31
Share capital
50,000.00 PLN
Registered address
Chrobrego 7, 43-200 Pszczyna, Poland
Electronic delivery address
AE:PL-73533-84924-VHCSU-24

Financials

Revenue history (in k)

Filing timeliness

Financial statements were filed on time, on average 49 days early.

  • 202522/06/2026
  • 202422/04/2025
  • 202326/06/2024
  • 202231/05/2023
  • 202124/05/2022
  • 202003/08/2021
Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Statistics

How the company ranks by revenue within its industry, region and across Poland in 2025.

Results vs industry

Revenue
This companyUSD 19.05kMedianUSD 229.84kAverageUSD 229.84k
Net profit
This companyUSD 614.28MedianUSD 636.15AverageUSD 636.15
Operating costs
This companyUSD 18.00kMedianUSD 228.90kAverageUSD 228.90k
Assets
This companyUSD 26.76kMedianUSD 156.52kAverageUSD 156.52k

Authorized Representatives

Witold Augustyn Kaczmarczyk – President of the Management Board
Stanisława Kaczmarczyk – Management Board Member

Manner of representation

Each member of the management board is authorized to represent the company independently.

Ownership

OwnerSharesShare valueStake
Stanisława Kaczmarczykage 68
50$6,753.1150%
Witold Augustyn Kaczmarczykage 71
50$6,753.1150%

Stanisława Kaczmarczyk and Witold Augustyn Kaczmarczyk hold a combined 100% – the ownership structure indicates family control.

Beneficial owners

Person

Bank accounts

Registered as a VAT taxpayer on 1993-07-05.

Debt

No entries in the National Debtors Register (KRZ).

Public aid

6 public aid cases recorded, with a total value of $21,446.

PurposeGross amount
Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts
$521
Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts
$18,462
Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts
$1,282

Competitors

Name
Biostat Research And Developmentsp. z o.o.
Hrmapasp. z o.o.
Medaisp. z o.o.
Novelty Hub TechnologicznyP.S.A.
HAPE Polskasp. z o.o.
4cell TherapiesS.A.
AI4Isp. z o.o.
Medical Algorithmssp. z o.o.
Magowiesp. z o.o.
Energatorsp. z o.o.

Change history

DateEvent
2007-03-20Share capital increase
2005-08-31Entered in the register

FAQ

Last updated: 2026-06-22